United States securities and exchange commission logo





                           August 13, 2020

       Steven O'Loughlin
       Chief Financial Officer
       Actinium Pharmaceuticals, Inc.
       275 Madison Avenue, 7th Floor
       New York, NY 10016

                                                        Re: Actinium
Pharmaceuticals, Inc.
                                                            Registration
Statement on Form S-3
                                                            Filed August 7,
2020
                                                            File No. 333-242322

       Dear Mr. O'Loughlin:

              This is to advise you that we have not reviewed and will not
review your registration
       statement.

               Please refer to Rules 460 and 461 regarding requests for
acceleration. We remind you
       that the company and its management are responsible for the accuracy and
adequacy of their
       disclosures, notwithstanding any review, comments, action or absence of
action by the staff.

                                                        Please contact Laura
Crotty at (202) 551-7614 with any questions.




                           Sincerely,


                           Division of Corporation Finance

                           Office of Life Sciences
       cc:                                              Rick Werner